Announcements Trials
Browse Landscape

Phase

Phase 2 88Phase 1 22Phase 1/2 21Phase 3 14Phase NA 9Phase 4 2Phase 2/3 2Phase EARLY_PHASE1 1

Status

Recruiting 1Completed 1

Sponsor Class

INDUSTRY 8OTHER 2NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Breast Neoplasms 2

Interventions

Dexamethasone 49Metformin 47Cyclophosphamide 42Saline Solution 38Cytarabine 34Sodium Chloride 32Bupivacaine 31Vincristine 27Cisplatin 26Propofol 25Methotrexate 25Letrozole 24Fluorouracil 24Dexmedetomidine 24Doxorubicin 23Fentanyl 22Carboplatin 22Etoposide 19Rituximab 18Morphine 18Bevacizumab 18Acetaminophen 18Lidocaine 17Granulocyte Colony-Stimulating Factor 17Prednisone 16Mercaptopurine 16Docetaxel 16Clomiphene 16Sevoflurane 15Ropivacaine 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 4 × OTHER × pegfilgrastim × Clear all
NCT05753618 2026-02-09

REaCT-OGF

Ottawa Hospital Research Institute

Phase 4 Recruiting
242 enrolled
Breast

Breast Neoplasms

NCT04781959 2025-03-21

A Randomized, Multicenter Pragmatic Trial Comparing Bone Pain From a Single Dose of Pegfilgrastim to 5 Doses of Daily Filgrastim in Breast Cancer Patients Receiving Neoadjuvant/Adjuvant Chemotherapy

Ottawa Hospital Research Institute

Phase 4 Completed
233 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡